ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

esmo.org

ESMO Virtual Advanced Course on KRAS targeting in NSCLC

Programme

ESMO VIRTUAL ADVANCED COURSE

13-14 OCTOBER 2021

Co-Chairs
Natasha Leighl, Canada
Marina Garassino, United States

ESMO VIRTUAL ADVANCED COURSE PROGRAMME
KRAS targeting in NSCLC

13-14 October 2021

CO-CHAIRS: Marina C. Garassino, United States
Natasha Leighl, Canada

SPEAKERS: Christine Bestvina, United States
Massimo Broggini, Italy
Grace Dy, United States
Pasi Janne, United States
Keith Kerr, United Kingdom
Colin Lindsay, United Kingdom
Laura Mezquita, Spain
Giulia Pasello, Italy
Adrian Sacher, Canada
Ferdinandos Skoulidis, United States
Egbert Smit, Netherlands

LEARNING OBJECTIVES

- Understanding the function and biology of KRAS in normal and malignant cells
- Gaining insights in the spectrum of KRAS molecular aberrations, platforms and strategies for molecular testing
- In depth discussion of emerging therapeutic strategies and clinical research in KRAS mutated NSCLC
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of KRAS G12C inhibition and beyond

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from

AMGEN®

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org

ESMO GOOD SCIENCE BETTER MEDICINE BEST PRACTICE

All timings are to be considered CEST (Central European Summer Time)

Wednesday, 13 October 2021

15:00-15:10 (10') **Welcome and introduction**
Natasha Leighl, CA

15:10-16:45 **Session 1 – KRAS Biology, Epidemiology, Pathology**

20' The structure, function and role of KRAS in normal cell homeostasis
Massimo Broggini, IT

20' Epidemiology of KRAS activating mutations: Incidence and biology across tumours with emphasis on lung cancer
Laura Mezquita, ES

20' Impact of co-mutations
Ferdinandos Skoulidis, US

20' Molecular tissue testing of NSCLC for KRAS mutations: who, how and when?
Keith Kerr, UK

15' Discussion

16:45-17:00 Break

17:00-18:30 **Session 2 – Targeting KRAS G12C in Lung Cancer**

20' Clinical development of KRAS G12C inhibitors – where are we now?
Pasi Janne, US

15' Resistance to KRAS G12C inhibitors – what do we know?
Grace Dy, US

20' Moving forward with KRAS G12C inhibitors – combinations, sequencing, early stage
Colin Lindsay, UK

20' Clinical cases and Expert Panel Discussion

10' with discussion – single agent case with liver toxicity, Giulia Pasello, IT

10' with discussion – combination therapy, Christine Bestvina, US

15' Discussion

Thursday, 14 October 2021

15:00–16:20 **Session 3 – Moving beyond KRAS G12C**

20' Targeting KRAS beyond G12C – what is coming?
Egbert Smit, NL

20' Targeting KRAS with checkpoint inhibitors
Marina C. Garassino, US

20' Vaccine and adoptive cell therapy strategies for the treatment of KRAS mutant NSCLC
Adrian Sacher, CA

20' Discussion

16:20–16:35 Break

16:35–18:05 **Workshop Sessions**
Three workshop sessions
10' Introduction based on clinical cases presented by speakers
20' Discussion

Workshop 1 Liquid biopsy applications for RAS-mutated mutational profiling, monitoring of disease course, clonal evolution and resistance in NSCLC
30' Laura Mezquita, ES
Natasha Leighl, CA
Keith Kerr, UK

Workshop 2 KRAS-focused vaccines and T cell therapies
30' Adrian Sacher, CA
Christine Bestvina, US

Workshop 3 Designing practice-changing trials – key considerations
30' Grace Dy, US
Colin Lindsay, UK
Marina C. Garassino, US

18:05–18:20 **Feedback on the workshops**
Marina C. Garassino, US
Natasha Leighl, CA

18:20–18:25 **Synthesis and wrap-up**
Marina C. Garassino, US